The coronavirus (COVID-19) pandemic is evolving very quickly and has affected healthcare systems worldwide. Many uncertainties remain about transplantation from a SARS-CoV-2-positive donor as only a few cases have been reported. Here, we present the successful transplantation of 2 kidneys from a 52-year-old male donor with active (2 weeks of COVID-19-like symptoms and positive nasopharyngeal swab SARS-CoV-2 polymerase chain reaction on the day of organ recovery) SARS-CoV-2 disease. The immediate postoperative course of both recipients was uneventful. This case emphasizes that patients with SARS-CoV-2 may be safe organ donors.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8209852 | PMC |
| http://dx.doi.org/10.1111/tid.13666 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
COVID-19 mortality among solid organ transplant recipients and candidates before specific vaccine availability in Colombia.
J Infect Dev Ctries
December 2024
Infectious Diseases Research Group, School of Medicine, Universidad Nacional de Colombia (National University of Colombia), Bogotá, Colombia.
Introduction: Coronavirus disease 2019 (COVID-19) is a life-threatening disease that was declared a pandemic in March 2020. Organ transplant recipients are vulnerable to infection and complications from COVID-19. The objective of this study was to investigate the rates of infection, mortality, and case-fatality ratios (CFR) in solid organ transplant recipients and patients on the waiting list for organ allocation in the period prior to the availability of specific vaccines.
View Article and Find Full Text PDFEpidemiological and Clinical Characteristics of the Course of COVID-19 Among Vaccinated and Unvaccinated Heart Transplant Recipients in Slovenia.
Vaccines (Basel)
December 2024
Infectious Diseases Department, University Medical Centre Ljubljana, 1000 Ljubljana, Slovenia.
: Patients receiving heart transplantation require lifelong immunosuppression and compared to the general population, they have a more than five times higher chance of acquiring COVID-19, and their mortality rates are higher. The aim of the present study was to estimate the epidemiological and clinical characteristics of COVID-19 in heart transplant recipients (HTRs) in Slovenia to estimate the vaccination rate and evaluate possible vaccination-hesitant subgroups. : All SARS-CoV-2-positive HTRs (N = 79) between 1 March 2020 and 31 December 2023 at the Infectious Diseases Department, University Medical Centre Ljubljana, Slovenia, were included retrospectively.
View Article and Find Full Text PDFApplication of nirmatrelvir/ritonavir for the treatment of severe COVID-19 in a 3-year-old child.
J Infect Dev Ctries
November 2024
Department of Pediatrics, Xinqiao Hospital, Second Affiliated Hospital of Army Medical University, Chongqing 400037, China.
Introduction: Nirmatrelvir/ritonavir (Paxlovid) is an effective antiviral drug for treating coronavirus disease 2019 (COVID-19) in adults. However, Paxlovid treatment of children, especially those who are under 12 years and with severe underlying diseases, is rare.
Case Report: A three-year-old COVID-19 patient (weighing 14.
Acceptance of Organs from Deceased Donors With Resolved or Active SARS-CoV-2 Infection: A Survey From the Council of Europe.
Transpl Int
December 2024
Infectious and Tropical Diseases Unit, Department of Medicine and Surgery, University of Insubria-Azienda Socio Sanitaria Territoriale (ASST)-Sette Laghi, Varese, Italy.
SARS-CoV-2 infection represents a new challenge for solid organ transplantation (SOT) with evolving recommendations. A cross-sectional survey was performed (February-June 2024) to describe practices among Member States of the Council of Europe (COE) on the use of organs from deceased donors with resolved or active SARS-CoV-2 infection. Overall, 32 out of 47 Member States with a transplant program participated in the study.
View Article and Find Full Text PDFCorrigendum to "The Use of SARS-CoV-2-Positive Donors in Hematopoietic Stem Cell Transplantation" [Transplant Proc, 2023. 55(8): p. 1810-1814.].
Transplant Proc
November 2024
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China. Electronic address:
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!